Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum9545110.26442/20751753.2021.4.200827ArticlesСтатьиReview ArticleThe role of microRNA in the diagnosis of cardiovascular diseases in obese patientsРоль микроРНК в диагностике сердечно-сосудистых заболеваний у пациентов с ожирениемShvangiradzeTeona A.ШвангирадзеТеона Альбертовна

канд. мед. наук

teona.endo@gmail.comBondarenkoIrina Z.БондаренкоИрина Зиятовна

д-р мед. наук

TroshinaEkaterina A.ТрошинаЕ. АClinic K+31АО «Клиника К+31»Endocrinology Research CentreФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России15042021234VOL 23, NO4 (2021)ТОМ 23, №4 (2021)35836228122021Copyright ©; 2021, Consilium MedicumCopyright ©; 2021, ООО "Консилиум Медикум"2021Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/95451

Obesity remains a global problem in modern society. It is commonly associated with an increased risk of cardiovascular diseases (CVD). The search for specific and sensitive biomarkers of CVD continues. Currently, a lot of studies focused on the potential role of microRNA (miRNA) in CVD development and progression. MiRNAs are involved in various pathological disorders associated with CVD. Endothelial dysfunction is considered as the initial step in the pathogenesis of many CVD, and atherosclerosis in particular. Altered expression of several miRNAs is associated with the development of endothelial dysfunction. Some miRNAs are considered as potential therapeutic targets. Further studies to evaluate the role of miRNAs in the pathogenesis of CVD are needed. It will improve the diagnosis and treatment of CVD in patients with obesity.

Ожирение остается глобальной проблемой современного общества и часто ассоциируется с повышенным риском сердечно-сосудистых заболеваний (ССЗ). Продолжается поиск высокоспецифичных и высокочувствительных биомаркеров ССЗ. В настоящее время активно проводятся исследования, направленные на изучение микроРНК (миРНК) в качестве новых потенциальных маркеров ССЗ. Роль миРНК описана для различных звеньев патогенеза ССЗ. Эндотелиальная дисфункция считается начальным этапом патогенеза многих ССЗ и атеросклероза в частности. Изменение экспрессии ряда миРНК ассоциируется с развитием эндотелиальной дисфункции, в том числе и при ожирении. Некоторые миРНК рассматриваются как потенциальные терапевтические мишени. Дальнейшее изучение роли миРНК в патогенезе ССЗ позволит персонифицировать стратегию по выделению группы пациентов с более тяжелым прогнозом.

obesityatherosclerosismicroRNAcardiovascular diseasesendothelial dysfunctionожирениеатеросклерозмикроРНКсердечно-сосудистые заболеванияэндотелиальная дисфункцияKhan LK, Bowman BA. Obesity: A major global public health problem. Annu Rev Nutr. 1999;19. DOI:10.1146/annurev.nutr.19.1.0Pi-Sunyer X. The medical risks of obesity. Postgrad Med. 2009;121. DOI:10.3810/pgm.2009.11.2074Zhou SS, Jin JP, Wang JQ, et al. MiRNAS in cardiovascular diseases: Potential biomarkers, therapeutic targets and challenges review-article. Acta Pharmacol Sin. 2018;39. DOI:10.1038/aps.2018.30Jonk AM, Houben AJHM, De Jongh RT, et al. Microvascular dysfunction in obesity: A potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology. 2007;22. DOI:10.1152/physiol.00012.2007Echahidi N, Mohty D, Pibarot P, et al. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation. 2007;116. DOI:10.1161/CIRCULATIONAHA.106.681304Vanhoutte PM. Endothelial dysfunction - The first step toward coronary arteriosclerosis. Circ J. 2009;73. DOI:10.1253/circj.CJ-08-1169Caballero AE. Endothelial dysfunction in obesity and insulin resistance: A road to diabetes and heart disease. Obes Res. 2003;11. DOI:10.1038/oby.2003.174Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018;34. DOI:10.1016/j.cjca.2017.12.005Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12. DOI:10.1038/nrg3074Tufekci KU, Oner MG, Meuwissen RLJ, Gent; 5. The role of microRNAs in human diseases. Methods Mol Biol. 2014;1107. DOI:10.1007/978-1-62703-748-8_3Pordzik J, Jakubik D, Jarosz-Popek J, et al. Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: Bioinformatic analysis and review. Cardiovasc Diabetol. 2019;18. DOI:10.1186/s12933-019-0918-xШвангирадзе Т.А., Бондаренко И.З., Трошина Е.А., Шестакова М.В. МикроРНК в диагностике сердечно-сосудистых заболеваний, ассоциированных с сахарным диабетом 2-го типа и ожирением. Терапевтический архив. 2016;88(10):87-92Iacomino G, Siani A. Role of microRNAs in obesity and obesity-related diseases. Genes Nutr. 2017;12. DOI:10.1186/s12263-017-0577-zKozomara A, Birgaoanu M, Griffiths-Jones S. MiRBase: From microRNA sequences to function. Nucleic Acids Res. 2019;47. DOI:10.1093/nar/gky1141Lewis BP, Shih IH, Jones-Rhoades MW, et al. Prediction of Mammalian MicroRNA Targets. Cell. 2003;115. DOI:10.1016/S0092-8674(03)01018-3Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23. DOI:10.1161/01.ATV.0000051384.43104.FCLerman A, Burnett JC. Intact and altered endothelium in regulation of vasomotion. Circulation. 1992;86.Lerman A, Zeiher AM. Endothelial function: Cardiac events. Circulation. 2005;111. DOI:10.1161/01.CIR.0000153339.27064.14Ignarro LJ. Endothelium-derived nitric oxide: actions and properties. FASEB J. 1989;3. DOI:10.1096/fasebj.3.1.2642868Epstein FH, Vane JR, Anggard EE, Botting RM. Regulatory Functions of the Vascular Endothelium. N Engl J Med. 1990;323. DOI:10.1056/nejm199007053230106Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004;15. DOI:10.1097/01.ASN.0000132474.50966.DAStapleton PA, James ME, Goodwill AG, Frisbee JC. Obesity and vascular dysfunction. Pathophysiology. 2008;15. DOI:10.1016/j.pathophys.2008.04.007Avogaro A, De Kreutzenberg SV. Mechanisms of endothelial dysfunction in obesity. Clin Chim Acta. 2005;360. DOI:10.1016/j.cccn.2005.04.020Gamez-Mendez AM, Vargas-Robles H, Rios A, Escalante B. Oxidative stress-dependent coronary endothelial dysfunction in obese mice. PLoS One. 2015;10. DOI:10.1371/journal.pone.0138609Austin RC, Lentz SR, Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ. 2004;11. DOI:10.1038/sj.cdd.4401451Kaplon RE, Chung E, Reese L, et al. Activation of the unfolded protein response in vascular endothelial cells of Nondiabetic obese adults. J Clin Endocrinol Metab. 2013;98. DOI:10.1210/jc.2013-1841Bharath LP, Cho JM, Park SK, et al. Endothelial Cell Autophagy Maintains Shear Stress-Induced Nitric Oxide Generation via Glycolysis-Dependent Purinergic Signaling to Endothelial Nitric Oxide Synthase. Arterioscler Thromb Vasc Biol. 2017;37. DOI:10.1161/ATVBAHA.117.309510lantorno M, Campia U, Di Daniele N, et al. Obesity, inflammation and endothelial dysfunction. J Biol Regul Homeost Agents. 2014;28.Zhang W, Yan L, Li Y, et al. Roles of miRNA-24 in regulating endothelial nitric oxide synthase expression and vascular endothelial cell proliferation. Mol Cell Biochem. 2015;405. DOI:10.1007/s11010-015-2418-yLi HT, Wang J, Li SF, et al. Upregulation of microRNA-24 causes vasospasm following subarachnoid hemorrhage by suppressing the expression of endothelial nitric oxide synthase. Mol Med Rep. 2018;18. DOI:10.3892/mmr.2018.9050Zheng Y, Li Y, Liu G,et al. MicroRNA-24 inhibits the proliferation and migration of endothelial cells in patients with atherosclerosis by targeting importin-a3 and regulating inflammatory responses. Exp Ther Med. 2018;15. DOI:10.3892/etm.2017.5355Chen W, Ou HS. Regulation of miR-24 on vascular endothelial cell function and its role in the development of cardiovascular disease. Sheng Li Xue Bao. 2016;68.Ren K, Zhu X, Zheng Z, et al. MicroRNA-24 aggravates atherosclerosis by inhibiting selective lipid uptake from HDL cholesterol via the post-transcriptional repression of scavenger receptor class B type I. Atherosclerosis. 2018;270. DOI:10.1016/j.atherosclerosis.2018.01.045Sun HX, Zeng DY, Li RT, et al. Essential role of microRNA-155 in regulating endotheliumdependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension. 2012;60. DOI:10.1161/HYPERTENSIONAHA.112.197301Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013;14. DOI:10.1007/s11154-012-9229-1Sayed D, Abdellatif M. AKT-ing via microRNA. Cell Cycle. 2010;9. DOI:10.4161/cc.9.16.12634Sun X, Lin J, Zhang Y, et al. MicroRNA-181b improves glucose homeostasis and insulin sensitivity by regulating endothelial function in white adipose tissue. Circ Res. 2016;118. DOI:10.1161/CIRCRESAHA.115.308166Chen JF, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 2006;38. DOI:10.1038/ng1725Sayed D, Abdellatif M. Micrornas in development and disease. Physiol Rev. 2011;91. DOI:10.1152/physrev.00006.2010Thum T, Catalucci D, Bauersachs J. MicroRNAs: Novel regulators in cardiac development and disease. Cardiovasc Res. 2008;79. DOI:10.1093/cvr/cvn137Maegdefessel L. The emerging role of microRNAs in cardiovascular disease. J Intern Med. 2014;276. DOI:10.1111/joim.12298Arunachalam G, Upadhyay R, Ding H, Triggle CR. MicroRNA signature and cardiovascular dysfunction. J Cardiovasc Pharmacol. 2015;65. DOI:10.1097/FJC.0000000000000178da Silva DCP, Carneiro FD, Almeida KC de, Bottino CFDS. Role of miRNAs on the pathophysiology of cardiovascular diseases. Arq Bras Cardiol. 2018;111. DOI:10.5935/abc.20180215Halushka PV, Goodwin AJ, MKH. Opportunities for microRNAs in the Crowded Field of Cardiovascular Biomarkers. Annu Rev Pathol. 2019;24:211-38. DOI:10.1146/annurev-pathmechdis-012418-012827£akmak HA, Demir M. Microrna and cardiovascular diseases. Balkan Med J. 2020;37:60-71. DOI:10.4274/balkanmedj.galenos.2020.2020.1.94Liu X, Dong Y, Chen S, et al. Circulating MicroRNA-146a and MicroRNA-21 Predict Left Ventricular Remodeling after ST-Elevation Myocardial Infarction. Cardiol. 2015;132. DOI:10.1159/000437090Widera C, Gupta SK, Lorenzen JM, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol. 2011;51. DOI:10.1016/j.yjmcc.2011.07.011Devaux Y, Mueller M, Haaf P, et al. Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain. J Intern Med. 2015;277. DOI:10.1111/joim.12183Goretti E, Vausort M, Wagner DR, Devaux Y. Association between circulating microRNAs, cardiovascular risk factors and outcome in patients with acute myocardial infarction. Int J Cardiol. 2013;168. DOI:10.1016/j.ijcard.2013.06.092Wang GK, Zhu JQ, Zhang JT, et al. Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010;31:659-66. DOI:10.1093/eurheartj/ehq013Shvangiradze T, Bondarenko I, Troshina E, et al. Profile of microRNAs associated with coronary heart disease in patients with type 2 diabetes. Obe Metab. 2016;13:34. DOI:10.14341/omet2016434-38